Xeris Biopharma (NASDAQ:XERS) Director John Johnson Sells 135,400 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 135,400 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director owned 698,083 shares of the company’s stock, valued at $5,040,159.26. This represents a 16.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Xeris Biopharma Stock Performance

XERS opened at $7.34 on Friday. The stock has a market capitalization of $1.22 billion, a PE ratio of -73.39 and a beta of 0.57. Xeris Biopharma Holdings, Inc. has a one year low of $3.14 and a one year high of $10.08. The business’s 50 day moving average price is $7.88 and its 200 day moving average price is $6.86.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The business had revenue of $74.38 million during the quarter, compared to the consensus estimate of $74.19 million. As a group, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XERS has been the subject of several research analyst reports. Barclays initiated coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Piper Sandler boosted their target price on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Zacks Research cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. Oppenheimer restated an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Institutional Trading of Xeris Biopharma

A number of large investors have recently made changes to their positions in the company. AlphaQuest LLC purchased a new position in Xeris Biopharma in the third quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after purchasing an additional 5,000 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in Xeris Biopharma in the third quarter valued at $68,000. Mercer Global Advisors Inc. ADV acquired a new stake in Xeris Biopharma in the third quarter valued at $85,000. Finally, FORA Capital LLC purchased a new stake in Xeris Biopharma during the 1st quarter worth about $60,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.